SYSTANE® Family - Meibomian Deficiency

Not Applicable

Completed

Interventions: Other: Microfiber towels (as warm compresses, with or without saline eye drops)
Other: SYSTANE® Lid Wipes
Other: SYSTANE® BALANCE
Dietary Supplement: SYSTANE® Vitamins

Brief Summary: The purpose of this study was to assess the efficacy of the SYSTANE® family of products (SYSTANE® Lid Wipes, SYSTANE® BALANCE Lubricant Eye Drops, and SYSTANE® Vitamins) on meibomian gland functionality in subjects with lipid deficiency related to evaporative dry eye as compared to the standard of care warm compresses.

Recruitment & Eligibility

Inclusion Criteria

Must have a clinical diagnosis of lipid deficient Evaporative Dry Eye;
Meibomian Gland Functionality - Not more than 6 glands yielding liquid secretion;
Must be willing to discontinue the use of all other Meibomian Gland; Dysfunction management prior to receiving the study test article at Visit 1, up until the end of the study period;
Must have best corrected visual acuity of 20/40 Snellen or better in each eye;
Must be able to follow instructions and be willing and able to attend required study visits;
Must read, sign, and date an Ethics Committee reviewed and approved informed consent form;
Other protocol-defined inclusion criteria may apply.

Exclusion Criteria

History or evidence of ocular or intraocular surgery or serious ocular trauma in either eye within the past 6 months;
Current punctal occlusion of any type (e.g., collagen plugs, silicone plugs);
History of intolerance or hypersensitivity to any component of the study medications;
History or evidence of epithelial herpes simplex keratitis (dendritic keratitis); vaccinia; active or recent varicella viral disease of the cornea and/or conjunctiva; chronic bacterial disease of the cornea and/or conjunctiva and/or eyelids; mycobacterial infection of the eye; and/or fungal disease of the eye;
Pregnant or lactating at the time of enrollment;
Not willing to take adequate precautions not to become pregnant during the study;
Use of any concomitant topical ocular medications during the study period;
Use of systemic medications that may contribute to dry eye unless on a stable dosing regimen for a minimum of 30 days prior to Visit 1;
Ocular conditions that may preclude the safe administration of either drop under investigation;
Unwilling to discontinue contact lens wear during the study period and for at least 1 week prior to Visit 1;
Participation in an investigational drug or device study within 30 days of entering this study;
Other protocol-defined exclusion criteria may apply.

Arm && Interventions

Group	Intervention	Description
Standard of Care	Microfiber towels (as warm compresses, with or without saline eye drops)	Microfiber towels (as warm compresses, with or without saline eye drops) warmed to the maximum comfortable temperature and placed over closed eyes for 8 minutes, 1 time a day. Duration of treatment was 3 months.
SYSTANE® Family	SYSTANE® Lid Wipes	SYSTANE® Lid Wipes administered to treated eye(s) once a day; SYSTANE® BALANCE lubricant eye drops administered to treated eye(s), 1 drop 4 times a day; SYSTANE® Vitamins, 2 softgels ingested daily. Duration of treatment was 3 months.
SYSTANE® Family	SYSTANE® BALANCE	SYSTANE® Lid Wipes administered to treated eye(s) once a day; SYSTANE® BALANCE lubricant eye drops administered to treated eye(s), 1 drop 4 times a day; SYSTANE® Vitamins, 2 softgels ingested daily. Duration of treatment was 3 months.
SYSTANE® Family	SYSTANE® Vitamins	SYSTANE® Lid Wipes administered to treated eye(s) once a day; SYSTANE® BALANCE lubricant eye drops administered to treated eye(s), 1 drop 4 times a day; SYSTANE® Vitamins, 2 softgels ingested daily. Duration of treatment was 3 months.

Primary Outcome Measures

Name	Time	Method
Number of Meibomian Glands Yielding Liquid Secretion (MGLYS)	Baseline, Month 1, Month 2, Month 3	Meibomian gland functionality was evaluated by the investigator using the Meibomian Gland Evaluator (MGE), a handheld instrument that provides a standardized method for applying consistent, gentle pressure to the outer skin of the lower eyelid. The total number of meibomian gland orificies evidencing liquid secretion during expression with the MGE, in both eyes, was recorded. A lower number of functioning meibomian glands may contribute to dry eye syndrome.

Secondary Outcome Measures

Name	Time	Method
Dry Eye Ocular Surface Disease Index (OSDI) Questionnaire Responses	Baseline, Month 1, Month 2, Month 3	The Dry Eye OSDI Questionnaire is a 12-question validated questionnaire \[resultant overall 0-100 score, with 0 being none of the time (best) and 100 being all of the time (worst)\] that measures ocular symptoms, visual function, and environmental factors that may affect a patient's vision. The OSDI questionnaire was completed by the patient with no assistance from the office staff, physician, or anyone else. Both eyes contributed to the mean.
Standard Patient Evaluation of Eye Dryness (SPEED) Questionnaire Responses	Baseline, Month 1, Month 2, Month 3	The Standard Patient Evaluation of Eye Dryness (SPEED) Questionnaire is a 16-question validated questionnaire (resultant overall score 0-28, with 0 being best and 28 being worst) that measures the frequency and severity of dry eye symptoms. The SPEED questionnaire was completed by the patient with no assistance from the office staff, physician, or anyone else. Both eyes contributed to the mean.